BriaCell Therapeutics Corp. (BCTX) vs Harvard Bioscience, Inc. (HBIO)
A side-by-side comparison of BriaCell Therapeutics Corp. and Harvard Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BCTX
BriaCell Therapeutics Corp.
$4.00HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT
HBIO
Harvard Bioscience, Inc.
$8.71HealthcareDelayed quote: Oct 6, 2026, 10:44 AM EDT
Total return — BCTX vs HBIO
growth of $100 · dividends reinvested · last 10yBCTX -99.9% (-52.2%/yr)HBIO -67.3% (-10.6%/yr)HBIO compounded faster over this window
Log scale — wide-divergence pair
BCTX HBIO
BCTX vs HBIO: by the numbers
- •HBIO is the larger company ($39M vs $35M market cap).
- •Both run net losses; BCTX's is the smaller (0.00% vs -11.86% net margin).
Metrics side by side
Valuation
| Metric | BCTX | HBIO |
|---|---|---|
| P/S ratio | N/A | 0.45 |
| P/B ratio | 1.45 | 5.30 |
| EV / EBITDA | N/A | 10.63 |
Profitability
| Metric | BCTX | HBIO |
|---|---|---|
| Gross margin | 0.00% | 58.16% |
| Operating margin | 0.00% | 1.17% |
| Net margin | 0.00% | -11.86% |
| ROE | -154.06% | -140.36% |
| ROIC | -164.58% | 1.99% |
Growth (annualized)
| Metric | BCTX | HBIO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -4.62% |
| Total return CAGR (5Y) | -67.32% | -34.33% |
Frequently asked
- How have BCTX and HBIO total returns compared?
- Over the past 10 years, BCTX delivered -52.81% and HBIO delivered -11.05% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.